OncoMatch/Clinical Trials/NCT06311851
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Is NCT06311851 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Bevacizumab for cancer.
Treatment: Bevacizumab — Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: liver resection
Prior liver resection
Cannot have received: transarterial chemoembolization
Previous TACE therapy received at other healthcare facilities
Lab requirements
Blood counts
platelet count >50×10^9 /L, hemoglobin >8.0 g/dL, ANC count ≥1.5 × 10^9/L
Kidney function
serum creatinine <1.5 times the upper limit of the normal range
Liver function
Child-Pugh class A or B; bilirubin <51 mmol/L; alanine and aspartate aminotransferase <3 times the upper limit of the normal range
Laboratory findings meeting specific criteria, including platelet count >50×10^9 /L, hemoglobin >8.0 g/dL, ANC count ≥1.5 × 10^9/L, bilirubin <51 mmol/L, alanine and aspartate aminotransferase <3 times the upper limit of the normal range, and serum creatinine <1.5 times the upper limit of the normal range.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06311851 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior liver resection, transarterial chemoembolization disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify